TEMPO.CO, Jakarta - A team of researchers from Padjadjaran University's Faculty of Medicine responsible for the clinical trial on CoronaVac candidate vaccine will soon produce a report on the three-month controlled vaccinations in Bandung.

The report is scheduled to be handed to the research's main sponsors, state-pharmaceutical firm BioFarma and the Indonesian Food and Drug Monitoring Agency (BPOM).

"The report will be completed in late December and will be handed over in early January," said Eddy Fadlyana, manager of the research team on December 29, 2020.

Sinovac Biotech's Covid-19 candidate vaccine clinical trial will be evaluated by the BPOM and compared to the study reports from similar vaccine developments conducted in Brazil and Turkey before issuing any form of emergency use.

"The first and second test phases were conducted in China," said Eddy.

Eddy stated that the three prominent aspects in the report that will be considered are the safety aspect of the candidate vaccine, the condition of the antibody, and its effectiveness against Covid-19.

Eddy also cited Turkey's clinical tests that produced a fantastic number of 91 percent while Brazil for the moment is reportedly 50 to 90 percent effective but will announce its complete clinical test result on January 7, 2021.

ANWAR SISWADI